Q-omics provides the consensus-scored MIR6812 profile across patient tissues and cancer cell-line models. MIR6812 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR6812 is differentially expressed in 12, with the highest sampling consensus in STAD. Additionally, MIR6812 RNA expression shows 10,652 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, STAD, and UVM as cancer lineages where MIR6812 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6812 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6812 survival associations across molecular data types. MIR6812 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6812 RNA expression–survival associations across cancer types. High MIR6812 expression shows unfavorable associations in PRAD, READ, UVM and LGG, but favorable associations in UCS and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR6812 RNA expression.
This table summarizes MIR6812 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6812. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6812 shows higher tumor expression in STAD, PAAD, COAD, UCEC, LIHC and BRCA. The STAD box plot shows higher MIR6812 RNA expression in tumor versus normal tissue (log2 FC = +0.690, t-test p < 0.001).
This table shows molecular features associated with MIR6812 in patient tissues and cancer cell lines. In patient samples, MIR6812 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
